News | April 23, 2024
AbbVie's phase 3 Select -GCA study of Upadacitinib showed positive results in patients with giant cell arteritis
Open a printable version of this pageEmail the URL of this page to a friend
Open a printable version of this pageEmail the URL of this page to a friend
NexGard Spectra is a soft, flavourful monthly chew that kills fleas before they can lay eggs
Longest survival follow-up ever reported for immunotherapy treatment in this setting
Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial
Decision marks the first approval in Europe for an anti-PD-1/L1 therapy in resectable NSCLC based on positive overall survival results
To accelerate the development of next-generation radioconjugates to treat cancer
Cureskin aims to disrupt the large and growing skin and hair care industry in India
Company reaffirms commitment to reduce the global burden of HPV-related diseases, including certain cancers
_Rupak_Singla_256_384.jpg)
Experts discussed the latest innovations, challenges, & collaborative solutions in the fight against TB at NHWIC-2024 held at AIIMS, Delhi
Keytruda is the first and only anti-PD-1 therapy approved in combination with chemoradiotherapy for these patients
Subscribe To Our Newsletter & Stay Updated
